Nasal Mometasone Dosing
For allergic rhinitis, use mometasone furoate nasal spray 50 mcg/spray at the following doses: children ages 2-11 years receive 1 spray per nostril once daily (total 100 mcg/day); adolescents and adults ages 12 years and older receive 2 sprays per nostril once daily (total 200 mcg/day); adults with nasal polyps receive 2 sprays per nostril twice daily (total 400 mcg/day). 1, 2
Age-Specific Dosing Algorithm
Children Ages 2-11 Years
- Dose: 1 spray (50 mcg) per nostril once daily
- Total daily dose: 100 mcg
- Duration consideration: Use for the shortest time necessary to achieve symptom control; consult physician if treatment exceeds 2 months per year due to potential growth effects 2
- Administration: Adult supervision required 2
Adolescents and Adults Ages 12+ Years
- Dose: 2 sprays (100 mcg) per nostril once daily
- Total daily dose: 200 mcg
- Timing flexibility: Morning or evening administration provides equivalent efficacy—patient preference determines timing 3
Adults with Nasal Polyps (Ages 18+)
- Dose: 2 sprays per nostril twice daily
- Total daily dose: 400 mcg
- This is the only indication requiring twice-daily dosing 1
Administration Technique
The FDA-approved technique requires specific steps to ensure full dosing 2:
- Prime the bottle when starting new bottle, after 1 week of non-use, or after cleaning (pump until fine mist appears)
- Shake well before each use
- Blow nose gently to clear nostrils
- Aim spray slightly away from nasal septum (center of nose)
- Spray while sniffing gently—press down once or twice per nostril based on age-appropriate dosing
- Clean nozzle weekly to prevent clogging and ensure consistent dosing
Clinical Context from Guidelines
The 2015 American Academy of Otolaryngology guidelines position intranasal corticosteroids as first-line therapy for allergic rhinitis 1. Mometasone furoate demonstrates efficacy within approximately 7 hours of first dose 4 and provides sustained symptom control with once-daily dosing for most indications.
Common pitfall: Do not exceed recommended doses. Higher doses do not improve efficacy and may increase adverse event risk 2. The most frequent adverse events are epistaxis, headache, pharyngitis, and viral infection, occurring at rates similar to placebo 1, 5.
For moderate-to-severe seasonal allergic rhinitis in patients ≥12 years, combination therapy with intranasal antihistamine may provide additional benefit, but mometasone monotherapy remains the evidence-based starting point 6, 7.
Pediatric safety note: Modern formulations like mometasone furoate show no significant impact on growth velocity when used at recommended doses, unlike older corticosteroid preparations 1, 5, 8. However, limit duration to what is clinically necessary and monitor growth in children requiring prolonged therapy.